Literature DB >> 21516824

[Metformin slows down ageing processes at the cellular level in SHR mice].

A V Arkad'eva, A A Mamonov, I G Popovich, V N Anisimov, V M Mikhel'son, I M Spivak.   

Abstract

It has been shown recently that metformin, the indirect mTOR-kinase inhibitor, significantly increases medium (by 37.8%) and maximum (by 10.3%) life span of SHR mice (Anisimov et al., 2008). We obtained fibroblasts from skin of 11-, 16-, 19- and 23-months-old SHR mice treated with metformin since the third and ninth day of life. We studied markers of cellular senescence in these fibroblasts. Significant differences were observed between the average number of senescence-associated heterochromatic foci (SAHF), the average of area nuclei and fluorescence intensity of nucleus after staining for gamma-H2AX in control and experimental animals. Also, we showed that metformin prevented the accumulation of fibroblasts with large area of nuclei; high activity of senescence-associated beta-galactosidase (SA-beta-gal), and high fluorescence intensity after staining for gamma-H2AX. It appears that accumulation of large quantity of senescence markers within a cell triggers it to enter the aging process. It appears that the increase of "old" cell population above the threshold disrupts the normal function of certain tissues, organs, and finally, the whole organism. It appears that metformin delays the "old" cells accumulation and prolongs the organism youth.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21516824

Source DB:  PubMed          Journal:  Tsitologiia        ISSN: 0041-3771


  7 in total

1.  Impacts of metformin and aspirin on life history features and longevity of crickets: trade-offs versus cost-free life extension?

Authors:  Harvir Hans; Asad Lone; Vadim Aksenov; C David Rollo
Journal:  Age (Dordr)       Date:  2015-04-02

Review 2.  Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials.

Authors:  R J Stevens; R Ali; C R Bankhead; M A Bethel; B J Cairns; R P Camisasca; F L Crowe; A J Farmer; S Harrison; J A Hirst; P Home; S E Kahn; J H McLellan; R Perera; A Plüddemann; A Ramachandran; N W Roberts; P W Rose; A Schweizer; G Viberti; R R Holman
Journal:  Diabetologia       Date:  2012-08-10       Impact factor: 10.122

3.  Effects of metformin, rapamycin, and resveratrol on cellular metabolism of canine primary fibroblast cells isolated from large and small breeds as they age.

Authors:  Ana Gabriela Jimenez; Sahil Lalwani; William Cipolli
Journal:  Geroscience       Date:  2021-03-17       Impact factor: 7.713

4.  Gerosuppressant metformin: less is more.

Authors:  Javier A Menendez; Sílvia Cufí; Cristina Oliveras-Ferraros; Luciano Vellon; Jorge Joven; Alejandro Vazquez-Martin
Journal:  Aging (Albany NY)       Date:  2011-04       Impact factor: 5.682

5.  If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice.

Authors:  Vladimir N Anisimov; Lev M Berstein; Irina G Popovich; Mark A Zabezhinski; Peter A Egormin; Tatiana S Piskunova; Anna V Semenchenko; Margarita L Tyndyk; Maria N Yurova; Irina G Kovalenko; Tatiana E Poroshina
Journal:  Aging (Albany NY)       Date:  2011-02       Impact factor: 5.682

6.  Alleviation of senescence and epithelial-mesenchymal transition in aging kidney by short-term caloric restriction and caloric restriction mimetics via modulation of AMPK/mTOR signaling.

Authors:  Dan Dong; Guang-Yan Cai; Yi-Chun Ning; Jing-Chao Wang; Yang Lv; Quan Hong; Shao-Yuan Cui; Bo Fu; Ya-Nan Guo; Xiang-Mei Chen
Journal:  Oncotarget       Date:  2017-03-07

Review 7.  Metformin in obesity, cancer and aging: addressing controversies.

Authors:  Lev M Berstein
Journal:  Aging (Albany NY)       Date:  2012-05       Impact factor: 5.682

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.